BioSpace News Archive

Sage today announced that, on February 1, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 113,000 shares of its common stock to sixteen new employees under Sage’s 2016 Inducement Equity Plan.

Arrowhead announced that it will host a webcast and conference call on Friday, February 9, 2018, at 4:30 p.m. EST to discuss its financial results for the fiscal 2018 first quarter ended December 31, 2017.

Statistically significant improvements in remyelination were demonstrated via quantitation of myelin using immunohistochemistry and transmission electron microscopy.

Dr. Reddy’s Laboratories announced today that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® (tetrabenazine) in the United States market approved by the U.S. Food and Drug Administration (USFDA).

Under the agreement signed, Innovus Pharma will be selling certain of its products directly to Wellmed’s current 500,000 customers and utilizing Wellmed’s access to a database of over 5 million additional potential consumers for a fixed cash fee if certain net revenue targets are met as a result of the direct mailing campaigns.

The notification states that the US patent 9,895,234 will be granted and enters into force on February 20, 2018.

Sosei today announced that it will be restating selected financial statements previously issued by the Company.

Portage Pharmaceuticals is providing an undisclosed funding to the new business along with a limited license to its CellPorter peptide delivery technology.

Worldwide sales were $10.4 billion for the fourth quarter of 2017, an increase of 3 percent compared with the fourth quarter of 2016, including a 1 percent positive impact from foreign exchange.

The subsequent offering period for the Offer, which commenced on January 22, 2018, expired as scheduled at 12:00 midnight, New York City Time, on January 31, 2018.